Market starts off 2023 with a bang, rebounds for winning week. Plus, a new Alzheimer’s drug approval. 1/6/23
CNBC's "Fast Money"
00:00
The Last Word Is a Disadvantage
Housing is going to be very hard for the market to turn, in my view, if housing does not. The FDA slapping its seal of approval on one Alzheimer's drug sending shares of biogen higher. One stock is on a roll as we kick off the new year.
Play episode from 12:34
Transcript
